EVOLENT HEALTH INC - CLASS A (EVH)

Four eVTOLs delivered and RMB25.7m revenue, with aerial media at ~40% of sales; EHang's board also approved a US$30m share repurchase program.

Over the last six months, Evolent Health’s shares have sunk to $3.96, producing a disappointing 5.7% loss - a stark contrast to the S&P 500’s 9.1% gain. This might have investors contemplating their next move.

Valuation remains challenged due to losses (negative P/E) and no dividend support, while the earnings call was constructive on guidance and growth initiatives but flagged meaningful near-term headwinds and leverage considerations. To see Spark’s full report on EVH stock, click here.

In our optimistic scenario for EVH, the stock could reach $12.00 over the next 12 months, representing a 207.7% gain from today's price. This scenario assumes favorable conditions materialize, including strong earnings growth, positive market sentiment, and successful execution of company ...

Track the latest Evolent Health (EVH) stock price, chart, market news, earnings, analyst ratings, and key financial data before trading or investing in Evolent Health.